Finland
3.3researchedPrescribing is genuinely liberal, mail order is legal, and 108,000 Finns bought obesity medication in 2025 paying 84m of 90m euros themselves. The hard block is ownership: only a licensed proviisori may hold a pharmacy licence, and the 2025 reform package deliberately left that untouched.
- Population
- 5.6m
- Currency
- EUR
- Region
- Nordic Europe
- Updated
- 2026-08-24
The six axes
Five is always better for an operator. Hover a label for the question it answers.
How it works here
Ownership is the block, and the 2025 reform did not move it [1][2]
Only a licensed proviisori granted an apteekkilupa may own a Finnish pharmacy. There were over 600 individual pharmacist-owners as of 2022.
The reform usually cited as relevant is real and has advanced: government proposal HE 111/2025 vp went to Parliament on 22 September 2025, and committee report StVM 30/2025 raised the pharmacy tax-free threshold from 200,000 to 250,000 euros with a two-year transition. It moves pharmacy taxation from turnover to margin, cuts prescription markups, and lets Fimea license non-pharmacy retailers for a defined low-risk self-care category.
None of it addresses who may own a pharmacy. Treat the ownership restriction as intact and not currently in play.
Prescribing is far more open than the ownership rule suggests [1][2][3]
No statutory video requirement was found. The operative framing, from the ministry in 2015 and still cited, is that remote healthcare services are generally comparable to traditional visits, with modality left to professional judgement.
Operator behaviour bears that out. MediLux offers video, phone or chat, including a no-charge chat tier. Laihdutuslääkäri lets the patient choose chat or video. euroClinix is explicitly questionnaire-based with an EU-authorised doctor and no video step at all.
Cross-border prescribing into Finland is real and operating. Viktenheten, a Swedish clinic run by Curevo Health AB, consults remotely with a Swedish physician, posts a paper prescription, and the patient fills it at a Finnish pharmacy such as Yliopiston Apteekki. That is a paper workaround rather than Kanta interoperability, which currently runs the other way: Finnish e-prescriptions are fillable in Estonia, Croatia, Latvia, Lithuania, Portugal, Poland, Czechia and Spain.
Reimbursement, and a contradiction resolved [1][2][3]
A widely repeated claim that Ozempic carries no Kela reimbursement even for diabetes is false. Kela lists semaglutide under codes 346 (restricted basic reimbursement) and 285 (restricted special reimbursement) for type 2 diabetes, alongside dulaglutide and liraglutide, requiring a B-lausunto, prior failure of at least one other drug class, and BMI 30 or above at initiation. The confusion comes from conflating the diabetes indication with the obesity indication.
For obesity only liraglutide is reimbursed, under code 3051, at the 40% basic rate, requiring BMI 35 plus prediabetes and treatment for hypertension or dyslipidemia, with a six-month initial window and a 5% weight-loss gate at twelve weeks to continue. Semaglutide for obesity gets nothing.
Prices [1][2]
Ozempic runs roughly 110 to 117 euros a month regardless of dose. Wegovy runs 180 to 280 euros. Mounjaro runs 219 to 590 euros depending on dose across the sources checked. Forma Medica charges 69 euros for an initial assessment, 330 euros for a new-patient programme including three consultations and prescriptions, and 350 euros a year for ongoing care.
Who is already there
| Name | Model | Price |
|---|---|---|
| Forma Medica | Fully video-based intake, monitoring and renewal, Finnish-licensed doctors | 69 euros initial, 330 euros new-patient programme, 350 euros/year ongoing |
| MediLux (TerveysProfiili Oy) | Video, phone or chat, including a Kela-subsidised 8 euro tier and a free chat option | 19 euros general, 69 euros obesity consult, medication 170 to 300 euros/month |
| Laihdutuslääkäri | Chat or video at the patient’s choice, Finnish doctors | n/a |
| euroClinix | Questionnaire-only, no video, EU-authorised doctor, all-inclusive pricing | From 379.95 euros per Mounjaro pen |
| Viktenheten (Curevo Health AB) | Swedish physician consults remotely, posts a paper prescription, patient fills at a Finnish pharmacy | n/a |
| Yliopiston Apteekki | Largest pharmacy operator, hosts an Etälääkärit remote-doctor section. GLP-1 coverage unconfirmed | n/a |
Routes in, and walls
What works viable
- A telehealth-only clinic with Finnish-licensed physicians prescribing via Kanta, fulfilled through an existing proviisori-owned apteekki verkkoapteekki.
- Cross-border prescribing from another Nordic country into Finnish pharmacies, which Viktenheten already does with posted paper prescriptions.
What does not blocked
- Owning a Finnish apteekki, or registering a foreign-owned entity as the online-pharmacy seller.
- Any "no prescription needed" framing. Several sites in this market use it, and it is a compliance red flag rather than a model.
How to make it work
The recommended entry path for a non-pharmacist operator running an own brand with a partner pharmacy. Read it against the six axes above, not instead of them.
Telehealth clinic with Finnish-licensed physicians prescribing via Kanta, fulfilled through an existing proviisori-owned pharmacy.
You cannot own the pharmacy: Finland reserves it to qualified pharmacists. Everything else is workable, the market is large relative to population, and cross-border prescribing from another Nordic country into Finnish pharmacies is already being done with posted paper prescriptions.
- Contract Finnish-licensed physicians and integrate with KantaThe national channel is the route; there is no captive pharmacy model to build.
- Partner with an existing verkkoapteekki for fulfilmentPharmacist ownership is the wall, so buy the capability rather than fighting for it.
- Test the cross-border paper route deliberatelyViktenheten already posts paper prescriptions in. Establish whether that scales or whether it is a workaround that will be closed.
Pharmacist-only ownership caps how much of the value chain you can hold, so you are always paying someone else for the dispensing.
Low capital. Good second Nordic market after Sweden.
What has happened
What we could not establish
Kept visible on purpose. These are the gaps a decision would have to close.
- What is the exact lääkelaki section number for the proviisori-only rule? Secondary sources cite chapter 6, commonly sections 40 and 41, but Finlex could not be read directly.
- Does Yliopiston Apteekki’s Etälääkärit service cover GLP-1 prescribing, or general telehealth only?
- Are there Finland-specific counterfeit or illegal-supply seizure figures? Only an EU-level Fimea warning was found.
Sources
Every non-obvious claim above links here. Confidence tags are applied strictly.